EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 417 filers reported holding EXELIXIS INC in Q1 2024. The put-call ratio across all filers is 0.60 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2023 | $10,074,912 | +65.8% | 419,963 | +51.0% | 0.04% | +33.3% |
| Q3 2023 | $6,075,065 | +854.0% | 278,035 | +734.4% | 0.03% | +900.0% |
| Q2 2023 | $636,803 | -66.5% | 33,323 | -66.0% | 0.00% | -66.7% |
| Q1 2023 | $1,901,928 | +885.5% | 97,987 | +828.8% | 0.01% | +800.0% |
| Q4 2021 | $193,000 | -96.0% | 10,550 | -95.4% | 0.00% | -96.8% |
| Q3 2021 | $4,823,000 | -40.3% | 228,131 | -31.0% | 0.03% | -53.7% |
| Q3 2020 | $8,085,000 | +85.4% | 330,665 | +80.0% | 0.07% | +34.0% |
| Q2 2020 | $4,360,000 | -74.1% | 183,658 | -73.1% | 0.05% | -88.1% |
| Q2 2017 | $16,841,000 | -10.4% | 683,740 | -21.2% | 0.42% | -8.5% |
| Q1 2017 | $18,800,000 | +60.1% | 867,549 | +10.1% | 0.46% | +81.7% |
| Q4 2016 | $11,745,000 | +853.3% | 787,715 | +399.3% | 0.25% | +620.0% |
| Q2 2016 | $1,232,000 | – | 157,757 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 15,001,073 | $320,572,000 | 64.48% |
| Sargent Investment Group, LLC | 432,125 | $9,235,000 | 4.22% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 443,534 | $9,483,000 | 3.52% |
| Bellevue Group AG | 3,878,800 | $82,890,000 | 1.42% |
| CAPITAL MANAGEMENT CORP /VA | 237,855 | $5,083,000 | 1.40% |
| Orbimed Advisors | 3,912,900 | $83,619,000 | 1.30% |
| Portolan Capital Management | 540,590 | $11,552,000 | 1.24% |
| TEALWOOD ASSET MANAGEMENT INC | 139,347 | $2,978,000 | 1.21% |
| Signition LP | 84,120 | $1,798,000,000 | 1.18% |
| Penn Capital Management Company, LLC | 529,630 | $11,318,000 | 1.12% |